Your browser doesn't support javascript.
loading
Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic.
Cabero-Martínez, Almudena; Sánchez-Guijo, Fermín; López-Corral, Lucía; Pérez, Estefanía; Avendaño, Alejandro; Baile, Mónica; Cabrero, Mónica; Martín, Ana-Africa; Rodríguez, Angela; Pérez, Balbina; Peña-Muñoz, Felipe; Román, Luz-Gema; Palomino, Danylo; López-Vázquez, Lourdes; Vidriales, María-Belén; González-Diaz, Marcos; Mateos, María-Victoria; Caballero, María-Dolores.
Affiliation
  • Cabero-Martínez A; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Sánchez-Guijo F; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • López-Corral L; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Pérez E; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Avendaño A; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Baile M; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Cabrero M; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Martín AA; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Rodríguez A; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Pérez B; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Peña-Muñoz F; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Román LG; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Palomino D; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • López-Vázquez L; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Vidriales MB; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • González-Diaz M; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Mateos MV; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
  • Caballero MD; Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain.
Front Med (Lausanne) ; 7: 462, 2020.
Article in En | MEDLINE | ID: mdl-32984363

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: Front Med (Lausanne) Year: 2020 Document type: Article Affiliation country: Spain Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Language: En Journal: Front Med (Lausanne) Year: 2020 Document type: Article Affiliation country: Spain Country of publication: Switzerland